Search

Your search keyword '"Pavoni, Matteo"' showing total 116 results
Start Over Author "Pavoni, Matteo"
116 results on '"Pavoni, Matteo"'

2. Effectiveness of high‐dose esomeprazole or pantoprazole 10‐day sequential therapy empirically prescribed in Helicobacter pylori‐infected naïve patients: a retrospective study.

Author

Pavoni, Matteo, Fiorini, Giulia, Zullo, Angelo, Saracino, Ilaria Maria, Gatta, Luigi, Manta, Raffaele, Imbrogno, Andrea, Lazzarotto, Tiziana, Borghi, Claudio, and Vaira, Dino

Subjects
*HELICOBACTER pylori, *BACTERIAL diseases, *TERRESTRIAL radiation, *MULTIVARIATE analysis, *PHYSICIANS
Abstract

Background and Aim Methods Results Conclusions Helicobacter pylori infection is one of the most common bacterial infections affecting humans, causing gastroduodenal and extraintestinal diseases. Treatment of the infection remains challenging for the clinicians, and different factors are involved in the failure of the therapeutic approach. The importance of the intensity of acid secretion inhibition remains an unclear issue. The aim of this study is to assess whether 80 mg/day esomeprazole‐based 10‐day sequential therapy (esomeprazole‐ST) achieved different eradication rates when compared to 80 mg/day pantoprazole‐based analogous regimen (pantoprazole‐ST).This was a retrospective observational study where data of consecutive patients referred by their physicians to our unit to perform an upper gastrointestinal endoscopy were analyzed.Overall, 1,327 patients were available for the analysis: 599 and 728 patients received pantoprazole‐ST and esomeprazole‐ST, respectively. Eradication rate was significantly higher in patients receiving esomeprazole‐ST (92.6%, 95% CI: 91–94.5) than pantoprazole‐ST (89.3%, 95% CI: 86.7–91.7; difference: 3.3%; 95% CI: 0.2–6.5; P = 0.037). Even after a multivariate analysis, the esomeprazole‐ST achieved a significantly higher eradiation (OR: 1.44; 95% CI: 1.1–2.17).This study showed that esomeprazole‐ST achieved significantly higher H. pylori cure rates than pantoprazole‐ST. Prospective and well‐designed trials are demander to confirm this prelaminar finding. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. CMV-RNAemia as new marker of active viral replication in transplant recipients

Author

Piccirilli, Giulia, primary, Lanna, Federica, additional, Gabrielli, Liliana, additional, Motta, Vincenzo, additional, Franceschiello, Martina, additional, Cantiani, Alessia, additional, Pavoni, Matteo, additional, Leone, Marta, additional, Borgatti, Eva Caterina, additional, Gibertoni, Dino, additional, Pascale, Renato, additional, Giannella, Maddalena, additional, Bonifazi, Francesca, additional, and Lazzarotto, Tiziana, additional

Published
2024
Full Text
View/download PDF

5. Mollaret's Meningitis due to Herpes Simplex Virus 2: A Case Report and Review of the Literature.

Author

Gabrielli, Liliana, Banchini, Isabella, Petrisli, Evangelia, Piccirilli, Giulia, Venturoli, Simona, Pavoni, Matteo, Cantiani, Alessia, Lanna, Federica, Campoli, Caterina, Montironi, Matteo, Giannella, Maddalena, and Lazzarotto, Tiziana

Subjects
HUMAN herpesvirus 2, LITERATURE reviews, NEUROLOGICAL disorders, CEREBROSPINAL fluid, MENINGITIS, FEVER, CEREBROSPINAL fluid examination
Abstract

Mollaret's meningitis is a rare neurological disorder characterized by recurrent episodes of aseptic lymphocytic meningitis, often associated with herpes simplex virus 2 (HSV-2) infection. We report the case of a 39 y.o. Italian woman who experienced four episodes of aseptic lymphocytic meningitis between 2004 and 2023, diagnosed as Mollaret's meningitis. In each episode, the patient presented with fever, severe headache and photophobia. In two episodes cutaneous vesicles in the left gluteal area preceding meningitis symptoms were also reported. A diagnostic evaluation included a physical–chemical analysis and a real-time PCR of the cerebrospinal fluid (CSF). The CSF presented pleocytosis with lymphocytic predominance and a positive HSV-2 load, with a peak of 1234 copies/mL. The patient was treated successfully with acyclovir, and the symptoms resolved without neurological sequelae. This case highlights the importance of comprehensive diagnostic testing and vigilant monitoring to manage Mollaret's syndrome effectively. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance

Author

Bujanda, Luis, primary, Nyssen, Olga P., additional, Ramos, June, additional, Bordin, Dmitry S., additional, Tepes, Bojan, additional, Perez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Castro-Fernandez, Manuel, additional, Lerang, Frode, additional, Leja, Mārcis, additional, Rodrigo, Luis, additional, Rokkas, Theodore, additional, Kupcinskas, Juozas, additional, Jonaitis, Laimas, additional, Shvets, Oleg, additional, Gasbarrini, Antonio, additional, Simsek, Halis, additional, Phull, Perminder S., additional, Buzás, György Miklós, additional, Machado, Jose C., additional, Boltin, Doron, additional, Boyanova, Lyudmila, additional, Tonkić, Ante, additional, Marlicz, Wojciech, additional, Venerito, Marino, additional, Vologzanina, Ludmila, additional, Fadieienko, Galina D., additional, Fiorini, Giulia, additional, Resina, Elena, additional, Muñoz, Raquel, additional, Cano-Català, Anna, additional, Puig, Ignasi, additional, García-Morales, Natalia, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Megraud, Francis, additional, Morain, Colm O., additional, Montes, Milagrosa, additional, and Gisbert, Javier P., additional

Published
2024
Full Text
View/download PDF

10. The Auditory Pathway in Congenitally Cytomegalovirus-Infected Human Fetuses.

Author

Gabrielli, Liliana, Bonasoni, Maria Paola, Piccirilli, Giulia, Petrisli, Evangelia, Venturoli, Simona, Cantiani, Alessia, Pavoni, Matteo, Marsico, Concetta, Capretti, Maria Grazia, Simonazzi, Giuliana, and Lazzarotto, Tiziana

Subjects
AUDITORY pathways, INNER ear, AUDITORY cortex, TEMPORAL lobe, BRAIN damage, SENSORINEURAL hearing loss
Abstract

Congenital cytomegalovirus (CMV) infection is the main cause of non-hereditary sensorineural hearing loss (SNHL). In order to shed light on SNHL pathophysiology, we examined the auditory pathway in CMV-infected fetuses; the temporal lobe, in particular the auditory cortex, and the inner ear. We investigated both inner ears and temporal lobes of 20 human CMV-infected fetuses at 21 weeks of gestation. As a negative group, five fetuses from spontaneous miscarriages without CMV infection were studied. Inner ears and temporal lobes were histologically examined, immunohistochemistry for CMV and CMV-PCR were performed. On the auditory cortex, we evaluated the local microglial reaction to the infection. CMV-positive cells were found in 14/20 brains and the damage was classified as severe, moderate, or mild, according to histological features. Fetuses with severe brain damage had a statistically higher temporal lobe viral load and a higher number of activated microglial cells in the auditory cortex compared to fetuses with mild brain damage (p: 0.01; p: 0.01). In the inner ears, the marginal cells of the stria vascularis were the most CMV positive. In our study, CMV affected the auditory pathway, suggesting a tropism for this route. In addition, in the auditory cortex, microglial activation may favor further tissue damage contributing to hearing loss. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Antimicrobial Resistance of Genital Mycoplasma and Ureaplasma: A Multicentre Study Over a 5-Year Period in Italy (2017–2021).

Author

Pavoni, Matteo, Principe, Luigi, Foschi, Claudio, Meroni, Elisa, Briozzo, Elena, Lazzarotto, Tiziana, Ambretti, Simone, and Di Bella, Stefano

Subjects
*UREAPLASMA, *AZITHROMYCIN, *DRUG resistance in microorganisms, *MYCOPLASMA, *MYCOPLASMATALES, *MIXED infections, *ANTIMICROBIAL stewardship
Abstract

Updated data on genital Mollicutes prevalence and antimicrobial susceptibility can help provide guidance for antibiotic stewardship and set up effective strategies for infection control policies. In this multicentre study, we assessed the prevalence and the resistance profile of Mycoplasma hominis (MH) and Ureaplasma species (U. parvum/U. urealyticum), analyzing data from 21,210 subjects who provided urogenital samples for Mollicutes detection by culture over a 5-year period (2017–2021) in two high-density urban areas in the North of Italy (i.e., Bologna and Lecco). Overall prevalence of Mollicutes infection was 22.3%, with women showing a significantly higher detection rate than men (p < 0.00001). The prevalence decreased with age (highest prevalence <30 years) and over the years considered. Ureaplasma strains were much more frequently detected (62.3%) compared to MH (8.3%) and to mixed infections (29.4%). Ureaplasma species showed high levels of ciprofloxacin resistance (39.5%), whereas MH strains were nonsusceptible to azithromycin and roxithromycin in about 60% of cases. Over time, a significant decrease of resistance to azithromycin and doxycycline was detected (p < 0.0001 and 0.0004, respectively), in parallel with an important increase of ciprofloxacin-resistance levels (p < 0.0001). Overall, our results revealed that minocycline and josamycin can be first-line drugs for Mollicutes empirical treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Respiratory Syncytial Virus-Load Kinetics and Clinical Course of Acute Bronchiolitis in Hospitalized Infants: Interim Results and Review of the Literature

Author

Piccirilli, Giulia, primary, Rocca, Alessandro, additional, Borgatti, Eva Caterina, additional, Gabrielli, Liliana, additional, Zama, Daniele, additional, Pierantoni, Luca, additional, Leone, Marta, additional, Totaro, Camilla, additional, Pavoni, Matteo, additional, Lazzarotto, Tiziana, additional, and Lanari, Marcello, additional

Published
2023
Full Text
View/download PDF

13. 129 - EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI EN FUNCIÓN DE LAS RESISTENCIAS ANTIBIÓTICAS: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Bujanda, Luis, primary, Nyssen, Olga P., additional, Ramos, June, additional, Bordin, Dmitry S., additional, Tepes, Bojan, additional, Pérez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Castro-Fernández, Manuel, additional, Lerang, Frode, additional, Leja, Marcis, additional, Rodrigo, Luis, additional, Rokkas, Theodore, additional, Kupcinskas, Juozas, additional, Jonaitis, Laimas, additional, Shvets, Oleg, additional, Gasbarrini, Antonio, additional, Simsek, Halis, additional, Phull, Perminder S, additional, Buzás, Gyorgiy Miklós, additional, Machado, Jose C., additional, Boltin, Doron, additional, Boyanova, Lyudmila, additional, Tonkic, Ante, additional, Marlicz, Wojciech, additional, Venerito, Marino, additional, Vologzanina, Ludmila, additional, Fadieienko, Galina D, additional, Fiorini, Giulia, additional, Resina, Elena, additional, Muñoz, Raquel, additional, Cano-Catalá, Anna, additional, Puig, Ignasi, additional, García-Morales, Natalia, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Megraud, Francis, additional, Morain, Colm O, additional, and Gisbert, Javier P., additional

Published
2023
Full Text
View/download PDF

15. Efficacy of a new nutraceutical formulation: L-tryptophan, probiotics, charcoal, chamomile, mint, and licorice (COLONIR®) in the improvement of gastrointestinal symptoms in subjects with irritable bowel syndrome

Author

FIORINI, Giulia, primary, SARACINO, Ilaria M., additional, PAVONI, Matteo, additional, NIPOTE, Bruno, additional, COLUCCI, Raffaele, additional, CAPONE, Pietro, additional, SANNINO, Angela, additional, FORTE, Fabrizio, additional, DE VERGORI, Emiliano, additional, BRANCACCIO, Mario, additional, CESAREO, Maurizio, additional, CASELLA, Giovanni, additional, MORREALE, Gaetano C., additional, BONFRATE, Leonilde, additional, PORTINCASA, Piero, additional, VINCENZI, Massimo, additional, COTTONE, Carmelo, additional, ORMANDO, Vittorio M., additional, SCALISE, Natale, additional, LAWSON, Paulin F., additional, BURATTINI, Osvaldo, additional, MONTALE, Amedeo, additional, LUZZA, Francesco, additional, ROSSI, Mauro, additional, VANNI, Riccardo, additional, BOZZI, Rosamaria, additional, VINCOLI, Giuseppina, additional, STEFANI, Nicoletta, additional, BORGHI, Claudio, additional, and VAIRA, Dino, additional

Published
2023
Full Text
View/download PDF

16. Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management

Author

Gatta, Gian Luigi, Nyssen, Olga P, Fiorini, Giulia, Saracino, Ilaria Maria, Pavoni, Matteo, Romano, Marco, Gravina, Antonietta Gerarda, Granata, Lucia, Pellicano, Rinaldo, Gasbarrini, Antonio, Di Leo, Alfredo, Losurdo, Giuseppe, Franceschi, Francesco, Nardone, Gerardo, Rocco, Alba, Dore, Maria Pina, Farinati, Fabio, Ghisa, Matteo, Bellini, Massimo, Holton, John, Puig, Ignasi, Vaira, Dino, Borghi, Claudio, Mégraud, Franci, O'Morain, Colm, Gisbert, Javier P, Gatta, Luigi, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Franceschi, Francesco (ORCID:0000-0001-6266-445X), Gatta, Gian Luigi, Nyssen, Olga P, Fiorini, Giulia, Saracino, Ilaria Maria, Pavoni, Matteo, Romano, Marco, Gravina, Antonietta Gerarda, Granata, Lucia, Pellicano, Rinaldo, Gasbarrini, Antonio, Di Leo, Alfredo, Losurdo, Giuseppe, Franceschi, Francesco, Nardone, Gerardo, Rocco, Alba, Dore, Maria Pina, Farinati, Fabio, Ghisa, Matteo, Bellini, Massimo, Holton, John, Puig, Ignasi, Vaira, Dino, Borghi, Claudio, Mégraud, Franci, O'Morain, Colm, Gisbert, Javier P, Gatta, Luigi, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), and Franceschi, Francesco (ORCID:0000-0001-6266-445X)

Abstract

Background and AimsThe optimal management of naive and not naive Helicobacter pylori patients remains unclear. Therefore, it is essential to evaluate whether the actual clinical practice mirrors the indications suggested by the guidelines. This study aimed to assess the effectiveness and the safety of the empirical first- and second-line treatments prescribed to patients enroled at Italian centres participating in the European Registry on H. pylori Management (Hp-EuReg). MethodsThe Hp-EuReg is an international multicentre prospective non-interventional registry starting in 2013 aiming to evaluate the management of H. pylori infection by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables assessed included demographics, previous eradication attempts, treatment regimen, effectiveness, and tolerance. ResultsOverall, 3723 patients from 2013 to February 2021 were included: 2996 and 727 received an empirical first- and second-line treatment, respectively. According to the modified ITT analysis, among the first-line regimens, only the bismuth quadruple therapy with three-in-one-single capsule (BQT-TSC), the concomitant, and the sequential treatment - all lasting 10 days - achieved an eradication rate >90%. Among the second-line regimens, only the 10-day BQT-TSC reported an effectiveness >90%. High-dose PPI twice daily also significantly increased the effectiveness of some therapies. The BQT-TSC was the regimen with the highest incidence of adverse events. ConclusionsOnly quadruple therapies lasting at least 10 days achieved over 90% eradication rates among the empirical first- and second-line regimens. It remains unclear whether high-dose PPI twice daily can improve the efficacy of quadruple treatment.

Published
2023

17. Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg).

Author

Nyssen, Olga P., Pratesi, Pietro, Spínola, Miguel A., Jonaitis, Laimas, Pérez-Aísa, Ángeles, Vaira, Dino, Saracino, Ilaria Maria, Pavoni, Matteo, Fiorini, Giulia, Tepes, Bojan, Bordin, Dmitry S., Voynovan, Irina, Lanas, Ángel, Martínez-Domínguez, Samuel J., Alfaro, Enrique, Bujanda, Luis, Pabón-Carrasco, Manuel, Hernández, Luis, Gasbarrini, Antonio, and Kupcinskas, Juozas

Subjects
HELICOBACTER pylori, MACHINE learning, HELICOBACTER pylori infections, PHENOTYPES, TREATMENT effectiveness, CLUSTER analysis (Statistics)
Abstract

The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection: All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the "most important" variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013–2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin–clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth–quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin–amoxicillin–metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. PAPEL DEL USO DE PROBIÓTICOS EN LA EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Casas, Diego, primary, Alcedo, Javier, additional, Lafuente, Miguel, additional, López, F. Javier, additional, Pérez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Saracino, Ilaria Maria, additional, Tepes, Bojan, additional, Jonaitis, Laimas, additional, Castro-Fernández, Manuel, additional, Carrasco, Manuel Pabón, additional, Huerga, Alma Keco-, additional, Voynovan, Irina, additional, Bujanda, Luis, additional, Lucendo, Alfredo J., additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Phull, Perminder S., additional, Rodrigo, Luis, additional, Lanas, Angel, additional, Martínez-Domínguez, Samuel J., additional, Alfaro, Enrique, additional, Fadieienko, Galina D, additional, Huguet, José M., additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupcinskas, Juozas, additional, Babayeva, Gülüstan, additional, Gridnyev, Oleksiy, additional, Leja, Mrcis, additional, Rokkas, Theodore, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Boltin, Doron, additional, Papp, Veronika, additional, Tonki, Ante, additional, Smith, Sinead M., additional, Simsek, Halis, additional, Venerito, Marino, additional, Boyanova, Lyudmila, additional, Milivojevic, Vladimir, additional, Kunovsky, Lumir, additional, Matysiak-Budnik, Tamara, additional, Marlicz, Wojciech, additional, Doulberis, Michael, additional, Cano-Català, Anna, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, Morain, Colm O., additional, and Gisbert, Javier P., additional

Published
2023
Full Text
View/download PDF

19. 140 - TRATAMIENTO ERRADICADOR DE SEXTA LÍNEA FRENTE A HELICOBACTER PYLORI: DATOS PRELIMINARES DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Nyssen, Olga P., primary, Garre, Ana, additional, Fiorini, Giulia, additional, Saracino, Ilaria Maria, additional, Pavoni, Matteo, additional, Vaira, Dino, additional, Phull, Perminder, additional, Beales, Ian, additional, Gasbarrini, Antonio, additional, Cano-Català, Anna, additional, Moreira, Leticia, additional, Mégraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional

Published
2023
Full Text
View/download PDF

20. 127 - IMPACTO DEL USO DE PROBIÓTICOS EN LA SEGURIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Casas, Diego, primary, Alcedo, Javier, additional, Lafuente, Miguel, additional, López, F. Javier, additional, Pérez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Saracino, Ilaria Maria, additional, Tepes, Bojan, additional, Jonaitis, Laimas, additional, Castro-Fernández, Manuel, additional, Pabón-Carrasco, Manuel, additional, Keco-Huerga, Alma, additional, Voynovan, Irina, additional, Bujanda, Luis, additional, Lucendo, Alfredo J., additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Phull, Perminder S., additional, Rodrigo, Luis, additional, Lanas, Angel, additional, Martínez-Domínguez, Samuel J., additional, Alfaro, Enrique, additional, Fadieienko, Galina D., additional, Huguet, Jose M., additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupcinskas, Juozas, additional, Babayeva, Gülüstan, additional, Gridnyev, Oleksiy, additional, Leja, Mrcis, additional, Rokkas, Theodore, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Boltin, Doron, additional, Papp, Veronika, additional, Tonki, Ante, additional, Smith, Sinead M., additional, Simsek, Halis, additional, Venerito, Marino, additional, Boyanova, Lyudmila, additional, Milivojevic, Vladimir, additional, Kunovsky, Lumir, additional, Matysiak-Budnik, Tamara, additional, Marlicz, Wojciech, additional, Doulberis, Michael, additional, Cano-Català, Anna, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, Morain, Colm O., additional, and Gisbert, Javier P., additional

Published
2023
Full Text
View/download PDF

21. 133 - PATRÓN DE PRESCRIPCIÓN DE PROBIÓTICOS ADYUVANTES A LA TERAPIA ERRADICADORA FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Casas, Diego, primary, Alcedo, Javier, additional, Lafuente, Miguel, additional, López, F. Javier, additional, Pérez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Saracino, Ilaria Maria, additional, Tepes, Bojan, additional, Jonaitis, Laimas, additional, Castro-Fernández, Manuel, additional, Pabón-Carrasco, Manuel, additional, Keco-Huerga, Alma, additional, Voynovan, Irina, additional, Bujanda, Luis, additional, Lucendo, Alfredo J., additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Phull, Perminder S., additional, Rodrigo, Luis, additional, Lanas, Angel, additional, Martínez-Domínguez, Samuel J., additional, Alfaro, Enrique, additional, Fadieienko, Galina D, additional, Huguet, José M., additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupcinskas, Juozas, additional, Babayeva, Gülüstan, additional, Gridnyev, Oleksiy, additional, Leja, Mrcis, additional, Rokkas, Theodore, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Boltin, Doron, additional, Papp, Veronika, additional, Tonki, Ante, additional, Smith, Sinead M., additional, Simsek, Halis, additional, Venerito, Marino, additional, Boyanova, Lyudmila, additional, Milivojevic, Vladimir, additional, Kunovsky, Lumir, additional, Matysiak-Budnik, Tamara, additional, Marlicz, Wojciech, additional, Doulberis, Michael, additional, Cano-Català, Anna, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, Morain, Colm O., additional, and Gisbert, Javier P., additional

Published
2023
Full Text
View/download PDF

23. Effectiveness of first and second‐line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management

Author

Gatta, Luigi, primary, Nyssen, Olga P., additional, Fiorini, Giulia, additional, Saracino, Ilaria Maria, additional, Pavoni, Matteo, additional, Romano, Marco, additional, Gravina, Antonietta Gerarda, additional, Granata, Lucia, additional, Pellicano, Rinaldo, additional, Gasbarrini, Antonio, additional, Di Leo, Alfredo, additional, Losurdo, Giuseppe, additional, Franceschi, Francesco, additional, Nardone, Gerardo, additional, Rocco, Alba, additional, Dore, Maria Pina, additional, Farinati, Fabio, additional, Ghisa, Matteo, additional, Bellini, Massimo, additional, Holton, John, additional, Puig, Ignasi, additional, Vaira, Dino, additional, Borghi, Claudio, additional, Mégraud, Francis, additional, O'Morain, Colm, additional, and Gisbert, Javier P., additional

Published
2022
Full Text
View/download PDF

26. Effectiveness of first and second‐line empirical treatment in Italy: Results of the European registry on Helicobacter pylorimanagement

Author

Gatta, Luigi, Nyssen, Olga P., Fiorini, Giulia, Saracino, Ilaria Maria, Pavoni, Matteo, Romano, Marco, Gravina, Antonietta Gerarda, Granata, Lucia, Pellicano, Rinaldo, Gasbarrini, Antonio, Di Leo, Alfredo, Losurdo, Giuseppe, Franceschi, Francesco, Nardone, Gerardo, Rocco, Alba, Dore, Maria Pina, Farinati, Fabio, Ghisa, Matteo, Bellini, Massimo, Holton, John, Puig, Ignasi, Vaira, Dino, Borghi, Claudio, Mégraud, Francis, O'Morain, Colm, and Gisbert, Javier P.

Abstract

The optimal management of naïve and not naïve Helicobacter pyloripatients remains unclear. Therefore, it is essential to evaluate whether the actual clinical practice mirrors the indications suggested by the guidelines. This study aimed to assess the effectiveness and the safety of the empirical first‐ and second‐line treatments prescribed to patients enroled at Italian centres participating in the European Registry on H. pyloriManagement (Hp‐EuReg). The Hp‐EuReg is an international multicentre prospective non‐interventional registry starting in 2013 aiming to evaluate the management of H. pyloriinfection by European gastroenterologists. Patients were registered in an e‐CRF by AEG‐REDCap. Variables assessed included demographics, previous eradication attempts, treatment regimen, effectiveness, and tolerance. Overall, 3723 patients from 2013 to February 2021 were included: 2996 and 727 received an empirical first‐ and second‐line treatment, respectively. According to the modified ITT analysis, among the first‐line regimens, only the bismuth quadruple therapy with three‐in‐one‐single capsule (BQT‐TSC), the concomitant, and the sequential treatment ‐ all lasting 10 days ‐ achieved an eradication rate >90%. Among the second‐line regimens, only the 10‐day BQT‐TSC reported an effectiveness >90%. High‐dose PPI twice daily also significantly increased the effectiveness of some therapies. The BQT‐TSC was the regimen with the highest incidence of adverse events. Only quadruple therapies lasting at least 10 days achieved over 90% eradication rates among the empirical first‐ and second‐line regimens. It remains unclear whether high‐dose PPI twice daily can improve the efficacy of quadruple treatment.

Published
2023
Full Text
View/download PDF

27. Rescue Therapies for H. pylori Infection in Italy

Author

De Francesco, Vincenzo, primary, Zullo, Angelo, additional, Gatta, Luigi, additional, Manta, Raffaele, additional, Pavoni, Matteo, additional, Saracino, Ilaria Maria, additional, Fiorini, Giulia, additional, and Vaira, Dino, additional

Published
2021
Full Text
View/download PDF

29. Culture-based antibiotic susceptibility testing for Helicobacter pylori infection: a systematic review.

Author

De Francesco, Vincenzo, Zullo, Angelo, Manta, Raffaele, Satriano, Alissa, Fiorini, Giulia, Pavoni, Matteo, Saracino, Ilaria M., Giostra, Fabrizio, Monti, Giorgio, and Vaira, Dino

Subjects
HELICOBACTER pylori infections, MICROBIAL sensitivity tests, HELICOBACTER pylori, BACTERIAL cultures, DRUG resistance in bacteria
Abstract

Background Primary antibiotic resistance in Helicobacter pylori (H. pylori) strains is increasing worldwide, affecting therapy success. The use of therapies tailored on susceptibility pre-testing at culture has been proposed, but data are still conflicting. Method We performed a systematic review to evaluate the role of a culture-based therapeutic approach for H. pylori treatment, taking into account the sensitivity of culture and the success rates achieved with tailored therapies in different therapeutic steps. Results We analyzed data from 51 studies. Overall, H. pylori strains were isolated in 80.7% of 7889 patients, the success rates being 78.1%, 77.5%, 86.3% and 86.6%, before first-, second-, third-line or more therapies, respectively. In comparative studies, the infection was cured in 89.9% of 2052 patients treated with tailored therapies, and in 77.6% of 2516 patients receiving empiric therapy (P<0.001). However, in the subanalysis, the tailored approach achieved optimal eradication rates (>90%) only when it was applied before first- and second-line therapies, but not before third-line or more attempts (<80%). Moreover, no significant difference emerged between the 2 approaches when data from only the most recent (last 5 years) studies were considered, as well as in those performed in Western populations. Conclusions The attempt to achieve antibiotic susceptibility testing before treatment failed in 20% of infected patients managed in dedicated laboratories. Culture-tailored therapies administered after 2 or more therapies achieved suboptimal eradication rates. The role of bacterial culture in patients whose therapeutic management failed to eradicate H. pylori probably needs to be corroborated by further data. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. Antimicrobial Efficacy of Five Probiotic Strains Against Helicobacter pylori

Author

Saracino, Ilaria Maria, primary, Pavoni, Matteo, additional, Saccomanno, Laura, additional, Fiorini, Giulia, additional, Pesci, Valeria, additional, Foschi, Claudio, additional, Piccirilli, Giulia, additional, Bernardini, Giulia, additional, Holton, John, additional, Figura, Natale, additional, Lazzarotto, Tiziana, additional, Borghi, Claudio, additional, and Vaira, Berardino, additional

Published
2020
Full Text
View/download PDF

35. Upper Endoscopy in Patients with Extra-Oesophageal Reflux Symptoms: A Multicentre Study

Author

Zullo, Angelo, primary, Fiorini, Giulia, additional, Bassotti, Gabrio, additional, Bachetti, Francesco, additional, Monica, Fabio, additional, Macor, Daniele, additional, Paoluzi, Omero Alessandro, additional, Scaccianoce, Giuseppe, additional, Portincasa, Piero, additional, De Francesco, Vincenzo, additional, Lorenzetti, Roberto, additional, Saracino, Ilaria Maria, additional, Pavoni, Matteo, additional, and Vaira, Dino, additional

Published
2020
Full Text
View/download PDF

38. Efficacy of a new nutraceutical formulation (CHETOGERD®) in patients with nonerosive reflux disease (NERD): a prospective observational study.

Author

Fiorini, Giulia, Saracino, Ilaria Maria, Pavoni, Matteo, Saccomanno, Laura, and Vaira, Dino

Abstract

Nonerosive reflux disease (NERD) is a gastrointestinal disorder that leads to symptoms such as heartburn and regurgitation without visible esophageal mucosal injury, and it is treated with proton-pump inhibitors (PPIs). CHETOGERD® gel or orosoluble (oro) formulations—an association of natural active ingredient: hyaluronic acid, altea, malva, apple active TM, Aloe vera, l-triptophan, calcium gluconate, sodium bicarbonate, Musa paradisiaca)—may be an alternative or a coadjutant treatment in patients with NERD. The aim of the study was to evaluate, prospectively, the efficacy of CHETOGERD® gel and oro in inducing symptom's reduction or remission, in consecutive patients with NERD. Patients were divided in two groups and treated with CHETOGERD® gel or CHETOGERD® oro, 3 sachets/day for 3 months, decreased to 1 sachet/day for other 3 months. Symptoms were evaluated at baseline, 3 and 6 months using the reflux disease questionnaire (RDQ). Symptoms' remission was defined as reduction of retrosternal pain or burning, epigastric pain or burning, regurgitation and acid sensation in mouth. Frequency, distribution analyses and non-parametric tests were used for the statistical analysis. Results were considered statistically significant for p values < 0.05. Four hundred and twenty-three patients (M/F 240/183; mean age 50 years) were diagnosed with NERD and were consecutively enrolled. 146 patients underwent therapy with CHETOGERD® gel, while 277 were treated with CHETOGERD® oro. 108 patients from the first group and 172 patients from the second group completed follow up at 3 months, while 100 patients from each group completed follow-up at 6 months. Both formulations were able to significantly reduce the frequency and intensity of symptoms analysed with RDQ. No adverse events were reported. CHETOGERD® gel and oro are two valid alternatives to control symptoms in patients with nonerosive reflux disease. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

43. Role of MIC levels of resistance to clarithromycin and metronidazole in Helicobacter pylori eradication.

Author

Francesco, Vincenzo De, Zullo, Angelo, Fiorini, Giulia, Saracino, Ilaria M, Pavoni, Matteo, Vaira, Dino, and De Francesco, Vincenzo

Subjects
DRUG resistance, METRONIDAZOLE, CLARITHROMYCIN, HELICOBACTER, GASTRITIS, ANTIBIOTICS, COMBINATION drug therapy, DRUG resistance in microorganisms, HELICOBACTER diseases, HELICOBACTER pylori, MICROBIAL sensitivity tests, TREATMENT effectiveness, PHARMACODYNAMICS
Abstract

Objectives: Antimicrobial resistance to clarithromycin and metronidazole significantly affects the cure rate of standard therapies for Helicobacter pylori infection. We tested whether different MIC levels of resistance to these antibiotics play a role in therapeutic efficacy.Methods: This was a post hoc analysis of data from a therapeutic trial in which patients with antibiotic susceptibility testing (Etest) received first-line sequential therapy. The level of antibiotic resistance was classified according to MIC values into low (MIC from >0.5 to ≤8 for clarithromycin, and from >8 to ≤32 for metronidazole) and high (MIC from >8 to 256 mg/L for clarithromycin, and from >32 to 256 mg/L for metronidazole).Results: Data from 1006 patients were included. There were 520 (51.7%) patients with susceptible strains, 136 (13.5%) with clarithromycin-resistant strains, 144 (14.3%) with metronidazole-resistant strains and 206 (20.5%) with clarithromycin-resistant and metronidazole-resistant strains. In the presence of double resistance, the cure rate was still high (38/41, 92.7%) when MIC levels were low and it was reduced (94/112, 83.9%) only when MIC levels of both antibiotics were high. The cure rates did not significantly differ between patients with single antibiotic-resistant strains, irrespective of MIC values, and those with susceptible strains.Conclusions: We found that MIC levels of resistance to either clarithromycin or metronidazole play a role in H. pylori therapy outcome and that bacterial resistance becomes relevant in vivo when clarithromycin-resistant and metronidazole-resistant strains have high MIC values for at least one of these antibiotics. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

44. PAPEL DEL USO DE PROBIÓTICOS EN LA EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)

Author

Casas, Diego, Alcedo, Javier, Lafuente, Miguel, López, F. Javier, Pérez-Aisa, Angeles, Pavoni, Matteo, Saracino, Ilaria Maria, Tepes, Bojan, Jonaitis, Laimas, Castro-Fernández, Manuel, Carrasco, Manuel Pabón, Huerga, Alma Keco-, Voynovan, Irina, Bujanda, Luis, Lucendo, Alfredo J., Jurecic, Natasa Brglez, Denkovski, Maja, Phull, Perminder S., Rodrigo, Luis, Lanas, Angel, Martínez-Domínguez, Samuel J., Alfaro, Enrique, Fadieienko, Galina D, Huguet, José M., Bordin, Dmitry S., Gasbarrini, Antonio, Kupcinskas, Juozas, Babayeva, Gülüstan, Gridnyev, Oleksiy, Leja, Mrcis, Rokkas, Theodore, Marcos-Pinto, Ricardo, Lerang, Frode, Boltin, Doron, Papp, Veronika, Tonki, Ante, Smith, Sinead M., Simsek, Halis, Venerito, Marino, Boyanova, Lyudmila, Milivojevic, Vladimir, Kunovsky, Lumir, Matysiak-Budnik, Tamara, Marlicz, Wojciech, Doulberis, Michael, Cano-Català, Anna, Hernández, Luis, Moreira, Leticia, Nyssen, Olga P., Megraud, Francis, Morain, Colm O., and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

45. 133 - PATRÓN DE PRESCRIPCIÓN DE PROBIÓTICOS ADYUVANTES A LA TERAPIA ERRADICADORA FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)

Author

Casas, Diego, Alcedo, Javier, Lafuente, Miguel, López, F. Javier, Pérez-Aisa, Angeles, Pavoni, Matteo, Saracino, Ilaria Maria, Tepes, Bojan, Jonaitis, Laimas, Castro-Fernández, Manuel, Pabón-Carrasco, Manuel, Keco-Huerga, Alma, Voynovan, Irina, Bujanda, Luis, Lucendo, Alfredo J., Jurecic, Natasa Brglez, Denkovski, Maja, Phull, Perminder S., Rodrigo, Luis, Lanas, Angel, Martínez-Domínguez, Samuel J., Alfaro, Enrique, Fadieienko, Galina D, Huguet, José M., Bordin, Dmitry S., Gasbarrini, Antonio, Kupcinskas, Juozas, Babayeva, Gülüstan, Gridnyev, Oleksiy, Leja, Mrcis, Rokkas, Theodore, Marcos-Pinto, Ricardo, Lerang, Frode, Boltin, Doron, Papp, Veronika, Tonki, Ante, Smith, Sinead M., Simsek, Halis, Venerito, Marino, Boyanova, Lyudmila, Milivojevic, Vladimir, Kunovsky, Lumir, Matysiak-Budnik, Tamara, Marlicz, Wojciech, Doulberis, Michael, Cano-Català, Anna, Hernández, Luis, Moreira, Leticia, Nyssen, Olga P., Megraud, Francis, Morain, Colm O., and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

46. 129 - EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORIEN FUNCIÓN DE LAS RESISTENCIAS ANTIBIÓTICAS: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)

Author

Bujanda, Luis, Nyssen, Olga P., Ramos, June, Bordin, Dmitry S., Tepes, Bojan, Pérez-Aisa, Angeles, Pavoni, Matteo, Castro-Fernández, Manuel, Lerang, Frode, Leja, Marcis, Rodrigo, Luis, Rokkas, Theodore, Kupcinskas, Juozas, Jonaitis, Laimas, Shvets, Oleg, Gasbarrini, Antonio, Simsek, Halis, Phull, Perminder S, Buzás, Gyorgiy Miklós, Machado, Jose C., Boltin, Doron, Boyanova, Lyudmila, Tonkic, Ante, Marlicz, Wojciech, Venerito, Marino, Vologzanina, Ludmila, Fadieienko, Galina D, Fiorini, Giulia, Resina, Elena, Muñoz, Raquel, Cano-Catalá, Anna, Puig, Ignasi, García-Morales, Natalia, Hernández, Luis, Moreira, Leticia, Megraud, Francis, Morain, Colm O, and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

47. 127 - IMPACTO DEL USO DE PROBIÓTICOS EN LA SEGURIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)

Author

Casas, Diego, Alcedo, Javier, Lafuente, Miguel, López, F. Javier, Pérez-Aisa, Angeles, Pavoni, Matteo, Saracino, Ilaria Maria, Tepes, Bojan, Jonaitis, Laimas, Castro-Fernández, Manuel, Pabón-Carrasco, Manuel, Keco-Huerga, Alma, Voynovan, Irina, Bujanda, Luis, Lucendo, Alfredo J., Jurecic, Natasa Brglez, Denkovski, Maja, Phull, Perminder S., Rodrigo, Luis, Lanas, Angel, Martínez-Domínguez, Samuel J., Alfaro, Enrique, Fadieienko, Galina D., Huguet, Jose M., Bordin, Dmitry S., Gasbarrini, Antonio, Kupcinskas, Juozas, Babayeva, Gülüstan, Gridnyev, Oleksiy, Leja, Mrcis, Rokkas, Theodore, Marcos-Pinto, Ricardo, Lerang, Frode, Boltin, Doron, Papp, Veronika, Tonki, Ante, Smith, Sinead M., Simsek, Halis, Venerito, Marino, Boyanova, Lyudmila, Milivojevic, Vladimir, Kunovsky, Lumir, Matysiak-Budnik, Tamara, Marlicz, Wojciech, Doulberis, Michael, Cano-Català, Anna, Hernández, Luis, Moreira, Leticia, Nyssen, Olga P., Megraud, Francis, Morain, Colm O., and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

49. Efficacy of a New Nutraceutical Formulation in Patients with Symptomatic Uncomplicated Diverticular Disease (SUDD): a Prospective Observational Study.

Author

D'Amico, Ferdinando, Fiorini, Giulia, Tursi, Antonio, Maria Saracino, Ilaria, Pavoni, Matteo, Danese, Silvio, and Vaira, Dino

Subjects
*LONGITUDINAL method, *PATIENT safety, *DISEASE remission, *SCIENTIFIC observation, *ABDOMINAL pain, *DIVERTICULOSIS
Abstract

Background & Aim: Symptomatic uncomplicated diverticular disease (SUDD) is characterized by abdominal pain, bloating and altered bowel habits (constipation or diarrhea) attributed to diverticula in the absence of macroscopic mucosal alterations. There is no consensus about management of these patients. DIVER-100®, an association of natural active ingredients may be effective in the treatment of patients with SUDD. The aim was to evaluate the efficacy and safety of DIVER-100® in patients with SUDD. Methods: We conducted a prospective observational study to evaluate the efficacy of DIVER-100® in consecutive patients with SUDD, confirmed by radiology or endoscopy. All patients were treated with DIVER-100® 2 capsules/day 10 days per month, for 3 months. The primary endpoint was the clinical remission rate, defined as the reduction of abdominal pain and bloating, improvement of bowel habits and prevention of acute diverticulitis (AD). The secondary endpoint was the rate of adverse events. Results: One hundred and one patients were consecutively enrolled at the Internal Medicine and Gastroenterology Unit, Sant'Orsola Hospital, Bologna, Italy. DIVER-100® was effective in inducing remission of symptoms in 12 patients (11.9%) at 3 months and in 10 patients (9.9%) at 6 months. DIVER-100® significantly reduced abdominal pain and bloating in 45.5% and 57.4% of patients respectively (p <0.001) after 3 months. No episodes of AD and no adverse events related to DIVER--100® were recorded at month 6 in the study population. Conclusions: DIVER-100® is a safe and effective nutraceutical compound in obtaining remission and symptom relief in SUDD patients. Further randomized, placebo-controlled clinical trials are needed to confirm these preliminary data. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

50. Rescue Therapies for H. pylori Infection in Italy

Author

Matteo Pavoni, Raffaele Manta, Luigi Gatta, Giulia Fiorini, Ilaria Maria Saracino, Dino Vaira, Angelo Zullo, Vincenzo De Francesco, De Francesco, Vincenzo, Zullo, Angelo, Gatta, Luigi, Manta, Raffaele, Pavoni, Matteo, Saracino, Ilaria Maria, Fiorini, Giulia, and Vaira, Dino

Subjects
Microbiology (medical), Drug, medicine.medical_specialty, Rifabutin, Microbiological culture, medicine.drug_class, media_common.quotation_subject, Antibiotics, RM1-950, Biochemistry, Microbiology, 03 medical and health sciences, 0302 clinical medicine, Levofloxacin, Internal medicine, antibiotic, medicine, Pharmacology (medical), General Pharmacology, Toxicology and Pharmaceutics, media_common, biology, Helicobacter pylori, business.industry, biology.organism_classification, H pylori infection, rescue therapy, Regimen, Infectious Diseases, therapy regimens, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Therapeutics. Pharmacology, business, retreatment, medicine.drug
Abstract

Background/Aims: Curing Helicobacter pylori infection remains challenging for clinicians, as no proposed first-line therapy achieves bacterial eradication in all treated patients so that several patients need two or more consecutive treatments. Bacterial culture with antibiotics susceptibility testing is largely unachievable in Italy, and empiric second-line and rescue therapies are generally used. This study aimed to identify what eradication regimens perform better in Italy, following first-line therapy failure. Methods: We performed a literature search on PubMed for studies on standard therapy regimens used as second-line or rescue treatments performed in adult patients. Studies including modified drug combinations were not considered. Both intention-to-treat and per- protocol analyses were computed for each therapy subgroup. Results: Data from 35 studies with a total of 4830 patients were eventually considered. As a second-line therapy, Pylera® (90.6%) and a sequential regimen (89.8%) achieved eradication rates significantly higher than other therapies. For third-line therapy, a levofloxacin-based regimen and Pylera® achieved comparable eradication rates (88.2% vs. 84.7%; p = 0.2). Among therapies used as fourth (or more) attempts, Pylera® and a rifabutin-based therapy achieved 77.4% and 66.4% cure rates, respectively (p = 0.013). A therapy sequence based on the type of first-line therapy used was proposed. Conclusions: Data obtained through our review indicate that standard therapies for H. pylori eradication can be used when following an appropriate sequence, allowing clinicians to improve the cure rate without resorting to bacterial culture.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results